Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Nov 02, 2021 4:22pm
154 Views
Post# 34079173

RE:RE:FYI

RE:RE:FYIWell this is interesting. They made a big push to "rebrand" specifically to the stock market. LSA revamped all the material, the pitch, how they discuss the company, etc... They did one "retail oriented" pitch.  Perhaps the view of her efforts was mostly tied in to new large investors, volume and the stock price -- the overall view of the company in the market.  It's changed a bit from it's depths, but probably not as much as PL or Board thinks it should. She could have been under heat for not figuring out how to engage all parts of the market and just didn't have the contacts to get that done or couldn't figure it out. 

It's an odd time for this to happen though if you think about it. Obviously we don't know what goes on day-to-day and situations arise, but generally I don't think this is a time the company would act unless there was some actual reason. If you know you have a milestone coming up that could change the perception of the company, you'd likely leave IR in that position and see how that development moves the needle. If that's the case, it may be more likely it was her doing.  Perhaps on to bigger and better things as a small company can only afford so much for IR efforts. Lots of reason why people leave. She may not have liked the remote issue, maybe doesn't think the rebrand will come about or the pipeline will develop --maybe the NASH extension was not helpful for her in being able to do what they asked of her. Maybe the fact she didn't get the Head of Communications job and may now report to that person rubbed her the wrong way.  Just speculating, but it would be odd time for them to act on her. 

Hate to say it, but she's not crucial to the IR efforts and the fact they had to pay someone outside the company to do what some of us on this board said to do and even provided them template points around means she must not have had a lot of ideas. I have to say, many on this board who have had to develop pitchbooks or reveiw material for their companies could see the  presentations needed a much more punchy, best-in-class makeover. It didn't seem to happen until LSA came in to the equation. Wish her luck as that was her chance to shine. Hope they can attract someone with even better qualifications and really continue upping the game.

I woudl also stress to THTX they should still have this person be in the US and they should have a demonstrable record of improving some biotechs IR efforts.  No more rookies with hope needed for them if things develop as we think they should. 


SPCEO1 wrote: I have been told by a none company source that her departure is official. I don't know if she left or was asked to leave.

SPCEO1 wrote: I suspect this means something, but it could just be some sort of screw up, but I have been told that Leah's phone number now gives a message that her number has been disconnected.

 




<< Previous
Bullboard Posts
Next >>